Clarius Group LLC Invests $273,000 in Moderna, Inc. (NASDAQ:MRNA)

Clarius Group LLC bought a new position in Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, Holdings Channel reports. The institutional investor bought 2,743 shares of the company’s stock, valued at approximately $273,000.

Several other hedge funds and other institutional investors have also bought and sold shares of MRNA. Cim Investment Management Inc. lifted its holdings in shares of Moderna by 4.2% in the 1st quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock worth $329,000 after acquiring an additional 86 shares during the last quarter. Cetera Advisor Networks LLC boosted its position in Moderna by 0.5% during the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock valued at $3,088,000 after buying an additional 87 shares during the period. Ancora Advisors LLC grew its stake in shares of Moderna by 41.2% during the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock valued at $51,000 after buying an additional 96 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in shares of Moderna by 7.5% in the first quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company’s stock worth $211,000 after buying an additional 100 shares during the period. Finally, Allworth Financial LP lifted its stake in shares of Moderna by 6.5% in the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after acquiring an additional 101 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on MRNA shares. Canaccord Genuity Group raised their price target on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday. HSBC reissued a “reduce” rating and set a $86.00 price target (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a research report on Tuesday, January 2nd. Finally, William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $126.49.

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $103.90, for a total value of $1,558,500.00. Following the transaction, the president now owns 1,516,063 shares in the company, valued at approximately $157,518,945.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Moderna news, President Stephen Hoge sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $103.90, for a total value of $1,558,500.00. Following the transaction, the president now directly owns 1,516,063 shares in the company, valued at $157,518,945.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Shannon Thyme Klinger sold 670 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $63,361.90. Following the sale, the insider now directly owns 8,557 shares of the company’s stock, valued at approximately $809,235.49. The disclosure for this sale can be found here. Insiders sold a total of 94,954 shares of company stock worth $9,966,476 in the last three months. 15.20% of the stock is currently owned by company insiders.

Moderna Price Performance

Shares of Moderna stock opened at $105.14 on Monday. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average of $99.86 and a 200 day moving average of $93.53. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $163.24.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. The business had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company’s quarterly revenue was down 44.9% compared to the same quarter last year. During the same quarter last year, the company earned $3.61 EPS. As a group, analysts anticipate that Moderna, Inc. will post -7.48 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.